Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Carves Deeper Niche Into CV Market With Staten Dyslipidemia Investment

17 Dec 2018

• By Jo Shorthouse

Novo gets to grips with cardiovascular • Source: Shutterstock

Related Content

Novo Nordisk CSO Outlines Obesity R&D Strategy, Calls Condition "Ticking Time Bomb"

13 Dec 2018

Life In The Old Dog Yet: Growth In Dyslipidemia Market Expected To 2025

17 Oct 2017

Related Companies

Novo Nordisk A/S

argenx N.V.

Arrowhead Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc.

Akcea Therapeutics, Inc.

Novartis AG

Pfizer Inc.

Gemphire Therapeutics, Inc.

Additional Topics

Deals Companies Clinical Trials Commercial Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.